LATEST HEMATOLOGY CONTENT

The Evolution of Treatment Goals in Immune Thrombocytopenia

Navigating the Nuances of Post-ESA Treatment in Lower-Risk MDS

Considerations With Luspatercept Failure in Lower-Risk MDS

Exploring Strategies in ESA-Refractory Lower-Risk MDS

Addressing Second-Line Approaches in Low-Risk MDS

Imetelstat Improves Outcomes in Heavily Transfusion-Dependent MDS

Duration of Response Contributes to Survival in COMMANDS Trial in MDS

Understanding the Importance of Transfusion Independence in MDS
CASE-BASED ROUNDTABLES
Advertisement
Advertisement

